Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed renal cell carcinoma~  * Metastatic or advanced/unresectable disease~* Measurable or nonmeasurable disease as defined by RECIST criteria~* No uncontrolled brain metastases~  * Patients with adequately treated brain metastases who are not taking anticonvulsants and corticosteroids may be eligible~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* Life expectancy ≥ 12 weeks~* WBC ≥ 3,500/mm³~* Platelet count ≥ 100,000/mm³~* Absolute granulocyte count ≥ 1,500/mm³~* Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min~* Bilirubin ≤ 1.5 mg/dL~* AST ≤ 2 times upper limit of normal (ULN)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or adequately treated stage I or II cancer from which the patient is currently in complete remission~* No known severe hypersensitivity to gefitinib or its excipients~* No incomplete healing from previous oncologic or other major surgery~* No unresolved chronic toxicity \> grade 2 from previous anticancer therapy (except alopecia and anemia)~* No evidence of clinically active interstitial lung disease~  * Patients with chronic stable radiographic changes who are asymptomatic are eligible~* No evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)~* No other significant clinical disorder or laboratory finding that would preclude study participation~PRIOR CONCURRENT THERAPY:~* More than 30 days since prior nonapproved or investigational drugs~* More than 6 weeks since prior aldesleukin or interferon and recovered~* At least 3 weeks since prior radiotherapy~* No prior gefitinib~* Prior chemotherapy or biological therapy allowed~* Prior or concurrent bisphosphonate therapy for bone metastases allowed~* No concurrent phenytoin, carbamazepine, rifampin, barbiturates, phenobarbital, or Hypericum perforatum (St. John's wort)~* No other concurrent agents specifically designed to inhibit the epidermal growth factor receptor (EGFR)~* No concurrent radiotherapy to measurable lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Gefitinib and PEG-IFNa Treatment (Type: EXPERIMENTAL): Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues